Mabwell Bioscience Co. Ltd. raised ¥3.48 billion ($547.9 million) in a Shanghai STAR Market IPO on Jan. 18 to support company R&D efforts and plans to build an antibody production plant. Though oversubscribed, the offering got a cool market reception, with shares plunging nearly 30% from a ¥32 open (US$27.96), then closing at ¥24.50 on the first day of trading before recovering slightly to ¥27.40 on Jan. 20.
While med-tech financings in 2021 fell about 17% below the amount raised in 2020, the industry still collected $49.26 billion, significantly more than each of the two previous years, and driven primarily by digital health and diagnostic technologies.
LONDON – Engitix Therapeutics Ltd. has raised $54 million in a series A round to advance early programs arising from its human extracellular matrix (ECM) target discovery platform towards the clinic with the support of new partner and equity investor Dompé Farmaceutici SpA.
Ceptur Therapeutics Inc. has completed a $75 million series A financing to develop targeted oligonucleotide therapies based on its U1 adaptor technology. The adaptors are bivalent oligonucleotides designed to engage sequence-specific mRNA and the U1 small nuclear ribonuclear protein that regulates transcription and splicing. The therapeutics are for controlling gene expression at the pre-mRNA level within the nucleus.
With an ambitious promise to unravel the biology of cellular rejuvenation programming, Altos Labs Inc. launched Jan. 19 with $3 billion in committed funding and an impressive roster of academic and industry leaders.
PARIS – Healshape SAS is preparing a $6.8 million series A round to develop a 3D bioprinted breast implant obtained from the patients' own cells. Supported by Pulsalys SAS, Lyon Saint-Etienne’s technology transfer acceleration company, this startup from Villeurbanne, France, has already benefited from more than a million dollars of French public funding and subsidies.
Cellusion Inc. recently closed a ¥1.1 billion ($9.5 million) financing, bringing its total 2021 fundraising to ¥1.7 billion. The company is preparing to enter the clinic with CL-S001, its corneal endothelial substitute cell candidate for treating corneal edema due to endothelial dysfunction, or bullous keratopathy.
RSS
